Oragenics to Present Concussion Treatment Progress at Sequire Investor Summit 2026

Oragenics Inc. (NYSE American: OGEN) announced that it will present at the upcoming Sequire Investor Summit 2026, scheduled for January 20-22, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. During the conference, the company plans to highlight its novel approach to addressing the significant unmet medical need in concussion and mild traumatic brain injury, including progress toward advancing its ONP-002 clinical program into Phase 2a studies. According to Oragenics Chief Executive Officer Janet Huffman, this is an area where no approved drug therapies currently exist.

The presentation matters because concussion and mild traumatic brain injury represent a substantial healthcare challenge with limited treatment options. The announcement signals Oragenics' continued commitment to developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company's lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for these conditions, with Phase 2a clinical trials progressing in Australia and U.S. Phase IIb trials planned to follow.

This development is important because successful treatments for concussion could have far-reaching implications for athletes, military personnel, accident victims, and others who experience traumatic brain injuries. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, suggesting broader therapeutic possibilities beyond concussion treatment alone.

The investor summit presentation provides Oragenics with a platform to showcase its progress to potential investors and partners at a critical juncture in the company's development. As noted in the company's newsroom available at https://ibn.fm/OGEN, this comes during a period of clinical advancement for the biotechnology firm. The implications extend beyond investor relations to potential patient benefits, as the development of effective concussion treatments could address a significant gap in neurological care.

BioMedWire, the specialized communications platform that distributed this announcement, focuses on the latest developments in biotechnology, biomedical sciences, and life sciences sectors. As part of the Dynamic Brand Portfolio at IBN, BioMedWire provides distribution through various channels including wire solutions, article syndication, and social media distribution. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.

The Sequire Investor Summit presentation represents an opportunity for Oragenics to demonstrate its progress in a therapeutic area that has seen limited pharmaceutical innovation despite significant patient need. The company's approach through intranasal delivery represents a novel method for targeting brain conditions, potentially offering advantages over traditional delivery methods. As clinical trials progress, the medical community will be watching for results that could establish new treatment paradigms for traumatic brain injury and related neurological conditions.